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bIP & Science, Thomson Reuters, London, UKThe financial burden of caring for 5.2 million people with
Alzheimer’s disease (AD) is $214 billion. This number will
rise to $1.2 trillion by 2050 if the projected tripling to 16
million cases does occur. Importantly, these estimates are
likely to be conservative, given the numerous causes of de-
mentia, underscoring the imperative for treatment. Further-
more, these numbers do not account for the emotional
costs to patients and their families.
Unfortunately, to date, there are no disease-modifying
medications. The presumption of failed clinical trial studies
is that intervention may be too late in the course of the dis-
ease [1]. Thus, current research on AD includes significant
effort to identify biomarkers decades before the threshold
for clinical diagnosis is met [2]. Most current biomarker
studies focus on measures of b amyloid (Ab) detected by
positron emission tomography (PET) imaging or measured
from cerebrospinal fluid [3–5]. However, nearly 75% of
cognitively normal individuals aged 70–79 years are free
of significant amyloid on PET imaging [6]. Furthermore,
studies of younger individuals show differences in brain
structure and cognitive ability related to APOE genotype sta-
tus [7] or vascular risk factors [8] at a time when pathologic
and in vivo measures of AD pathology are virtually absent.
These data suggest that factors other than cerebral amyloid-
osis during early life may result in increased risk for later-
life dementia.
There is mounting evidence suggesting a more variable
profile in which indices of the neurodegenerative processes
(as indicated by changes in cognitive and brain structure)
may precede amyloidosis [9]. Despite results that challenge
the Ab model for AD pathogenesis, most clinical trial
studies remain centered around amyloid as the primary
target for drug development [10,11]. We propose that the
reason clinical trial studies have largely failed is because
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(http://creativecommons.org/licenses/by/4.0/).AD is a single disease. In fact, it has been well
documented that sporadic AD is a heterogeneous disease
[12]. Decades ago, the variability of the AD profile and its
implication were more widely considered [13–15], but
once the NINCDS-ADRDA diagnostic criteria was put
into widespread practice, it was largely abandoned. This
may be because the definite diagnosis of dementia depends
on autopsy data, requiring widespread distribution of
amyloid plaques and neurofibrillary tangles for diagnosis
[16]. Neuropathologic studies, however, suggest that other
pathologies often co-occur and at times may lead to ante-
mortem diagnosis of AD, even when neuropathologic
criteria are not met [12].
Consider now cancer as a model for rethinking the treat-
ment strategy for AD. Like AD, cancer at its end stages is
widespread and etiology is difficult to determine. Today,
the diagnosis of cancer itself is uninformative. Rather
research has determined that there are over 100 different
types of cancers, identified in part by symptom variability.
As a result of recognizing multiple forms of the disease,
drug treatments target each type. Currently, a cancer diag-
nosis requires additional testing to pinpoint subtype and
stage. Depending on the answer, different treatment options
are considered. For the diagnosis of leukemia alone, there
are over 70 treatment options.
For AD, many different drug discovery studies are
ongoing but there is no overt strategy of identifying the
“types of AD” as potential targets for different drug treat-
ment. Our analogy to cancer is not a clean one. Cancer is a
different disease in which biopsy can differentiate between
cancer cells and normal ones. The current work on AD bio-
markers, however, is an equivalent attempt to find the
earliest indicator of disease, similar to detecting preclinical
cancer cells.
Through biomarker research, the evidence suggests that
there are people who are symptomatic for AD that have am-
yloid and those who do not. Furthermore, there are people
without cognitive impairment who have amyloid and those
who do not. On commonly used assessment methods, cogni-
tive impairment profiles include those that areeimer’s Association. This is an open access article under the CC BY license
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almost every positive study in favor of a particular AD risk
factor or biomarker, there are contradictory negative find-
ings.
We submit that the primary question we should collec-
tively seek to answer is whether the path to effective AD
treatment lies in identifying ADs, potentially resulting in
multiple drug targets rather than one. It is likely that the
data needed to support this hypothesis have already been
generated. A shift from the presumption of a single disease
to multiple diseases would reframe the drug development
strategy for AD. Although there have been and continue to
be clinical trial studies of unique drug compounds, they all
are based on the same premise of seeking a cure for a single
disease which has been well documented as heterogeneous
in nature. Current research has presumed that the failure of
past studies stems from intervention that has occurred too
late in the disease process and thus much money and effort
is being spent on trying to target the disease at its earliest
stages. Doing so has resulted in trying to identify people at
risk for disease based on specific clinical profiles, including
still uncertain expensive biomarkers that require procedures
that can be invasive and thus lead to inherently biased study
samples. The difference between what we are proposing and
what is currently being done is we contend that AD is not a
heterogeneous disease, it is multiple diseases, and each type
is expressing itself, even at the asymptomatic stages, through
these varying clinical profiles. Once each type is identified,
the opportunity exists for finding its unique drug target.
In summary, the focus of future Alzheimer’s research
should be on:
1. Identifying AD subpopulations
2. Understanding the structure of each population based
on the molecular data
3. Building stratification model(s) (for disease subtypes,
drug response, and prognosis)
4. Identifying new therapeutic targetsClosing remarks
Expression-based classification of patients into groups of
interest has been a challenge due to patient heterogeneity.
One potential solution to overcome some of these challenges
has been to use prior knowledge in the form of information
around known signaling pathways or protein-protein interac-
tion networks into the statistical analysis procedure, result-
ing in a more integrated approach. The activity of these
entire pathways or networks is then used, rather than
the expression levels of single genes, to stratify patients
into their respective groups. It has been shown in a number
of studies that these approaches based on utilization of
prior knowledge achieve better results (e.g. accuracy, repro-
ducibility and robustness of the models) than purely
data-driven approaches for such applications as biomarker
identification, patient stratification [17,18], and clustering
analysis for subgroup identification [19]. Moreover, theseapproaches subsequently allow for a wide spectrum of
unique applications, such as mechanism reconstruction and
drug target identification [20].
Four decades after the United States declared a “war” on
cancer, there have been battles won and plenty of advances
but no final victory. The medical field has spent far fewer
years with a similar focus on Alzheimer’s; it was only 2
years ago the Obama administration unveiled a national
plan to find a cure by 2025. We, the authors, think that by
asking the question of finding a cure for a disease, rather
than multiple diseases, we are impeding our ability to under-
stand what the data we already have on hand are trying to tell
us. We could well be on the brink of “controlling” AD but to
push us to the other side of increasing treatment success, we
need to re-evaluate what we are trying to target. We further
posit that the likely best cure for AD is in its prevention. As
we gain success in sharpening our understanding of the bio-
markers for each type of disease at its earliest stages, we will
also enhance identification of effective prevention strategies.
Before there is a cure or as we have argued, cures, society
needs to promote interventional strategies to lessen the dis-
ease’s impact on those already showing risk for disease. The
alternative is finding ourselves on an ever-widening abyss,
into which many of our loved ones, friends, and colleagues
are likely to fall.References
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